Study guide

6.3 ADME Rates, Half-Lives, and Compartment Models

NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the FPGEE 1.2 How to Use This Study Guide

2 Chapter 2: Foundational Biomedical Sciences I

2.1 Anatomy 2.2 Physiology 2.3 Biochemistry

3 Chapter 3: Foundational Biomedical Sciences II

3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases

4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry

4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions

5 Chapter 5: Pharmacology and Toxicology

5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes

6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics

6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics

7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems

7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics

8 Chapter 8: Public Health, Practice Management, and Biostatistics

8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods

9 Chapter 9: Professional Communication and Behavioral Aspects

9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice

10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment

10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education

11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care

11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine

12 Chapter 12: Clinical Sciences III — Evidence-Based Practice

12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability

13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products

13.1 Self-Care and Natural Products

6.3 ADME Rates, Half-Lives, and Compartment Models

Key Takeaways Explain This Topic AI

Bioavailability after oral dosing is reduced by incomplete absorption and hepatic first-pass metabolism; IV bioavailability is 1.0 by definition.

Volume of distribution (Vd) relates dose to plasma concentration; Vd far exceeding total body water indicates extensive tissue binding (e.g., digoxin, chloroquine).

Half-life t1/2 = 0.693·Vd/CL governs dosing interval, accumulation, and time to steady state (4-5 half-lives).

The two-compartment model produces a biexponential concentration-time curve with distinct distribution (alpha) and elimination (beta) phases; one-compartment models apply when distribution is near-instant.

Cockcroft-Gault estimation of creatinine clearance guides renal dose adjustment for renally cleared drugs.

Last updated: July 2026

Absorption and Bioavailability

Absorption describes drug movement from the site of administration into systemic circulation. Bioavailability (F) is the fraction of administered dose reaching systemic circulation unchanged.

Intravenous (IV) — F = 1.0; instantaneous peak; no absorption barrier.

Intramuscular (IM) / Subcutaneous (SC) — water solutions absorb rapidly; oil depots slow release.

Oral (PO) — the most common but most variable route; subject to gut transit, solubility, permeability, and first-pass metabolism in the gut wall and liver. Propranolol, morphine, and lidocaine have high extraction ratios and low oral bioavailability despite complete absorption.

Sublingual / buccal — bypass portal circulation; nitroglycerin reaches systemic circulation quickly.

Topical / transdermal — local effect or systemic delivery through intact skin.

Rectal — partial bypass of first-pass; useful when vomiting or unconscious.

Inhalation — local delivery to lung minimizes systemic exposure for beta-agonists and corticosteroids.

Distribution

Volume of distribution (Vd) is the apparent volume that would be required to contain the total body drug at the measured plasma concentration: Vd = Dose / C0. Vd is a theoretical, not anatomic, volume.

Vd ≈ 3-5 L: drug largely confined to plasma (warfarin, heparin — high plasma protein binding).

Vd ≈ 15-18 L: extracellular water (small polar drugs).

Vd ≈ 42 L: total body water (ethanol, theophylline).

Vd >> 100 L: extensive tissue or fat binding (digoxin ~500 L, chloroquine ~13,000 L, amiodarone ~60 L/kg).

Protein binding — acidic drugs bind albumin; basic drugs bind alpha1-acid glycoprotein (an acute-phase reactant, rises in inflammation). Only free drug distributes, is metabolized, and excretes; displacement interactions raise free fraction transiently but rarely matter clinically unless Vd is small and clearance is low.

Blood-brain barrier (BBB) — tight junctions and efflux transporters (P-gp, BCRP) exclude hydrophilic and large molecules; lipophilic small molecules cross by passive diffusion. Inflammation (meningitis) partially opens the BBB, allowing penicillin to reach therapeutic CSF concentrations.

Metabolism and Excretion

Hepatic clearance : CLh = Qh · E, where Qh is hepatic blood flow (~90 L/h) and E the extraction ratio.

High-extraction drugs (E > 0.7; morphine, propranolol, verapamil) — clearance is blood-flow-limited; sensitive to hepatic blood flow changes (heart failure) but relatively insensitive to protein binding or enzyme induction.

Low-extraction drugs (E < 0.3; warfarin, phenytoin, diazepam, theophylline) — clearance is capacity-limited; sensitive to enzyme induction/inhibition and protein binding.

Renal clearance combines glomerular filtration (GFR ~120 mL/min), active tubular secretion (OAT/OCT transporters in proximal tubule), and passive reabsorption (lipophilic weak acids/bases reabsorbed when urine pH favors the uncharged form).

Creatinine clearance (CrCl) is estimated by Cockcroft-Gault :

CrCl (mL/min) = [(140 − age) × weight (kg)] / (72 × SCr)

Multiply by 0.85 for females (standard Cockcroft-Gault sex correction). Many drug labels reference Cockcroft-Gault for renal dose adjustment. The 2021 CKD-EPI equation estimates GFR (eGFR) but is not always interchangeable for drug dosing.

Half-Life, Clearance, and Steady State

Half-life is the time for plasma concentration to fall by 50%: t1/2 = 0.693 · Vd / CL . It governs:

Dosing interval — drugs with short t1/2 need frequent dosing or sustained-release formulation.

Time to steady state — after 4-5 half-lives, accumulation equals elimination and the patient reaches ~94-97% of steady state. Doubling the dose does NOT shorten time to steady state; it only raises the steady-state concentration.

Washout — similarly 4-5 half-lives for near-complete elimination.

Clearance (CL) is the volume of plasma cleared of drug per unit time: CL = Rate of elimination / C. Total body clearance is the sum of renal and non-renal clearances.

Compartment Models

  • Feature One-compartment Two-compartment Non-compartmental
  • Body representation Single well-stirred tank Central + peripheral compartments No structural assumptions
  • Concentration-time curve Monoexponential Biexponential (alpha + beta) Empirical; trapezoidal AUC
  • Key parameters Vd, k, t1/2 Vc, Vp, Vss, k12, k21, k10 AUC, AUMC, MRT, CL, Vss

Best for Drugs distributing rapidly (e.g., aminoglycosides) Distribution-limited drugs (e.g., digoxin, lidocaine) Bioequivalence, exposure comparisons

In a two-compartment model , IV bolus produces a curve with an early steep distribution (alpha) phase as drug leaves plasma for tissues, followed by a slower elimination (beta) phase whose slope gives the terminal half-life used in dosing.

Linear vs Nonlinear Pharmacokinetics

Linear PK — clearance, Vd, and t1/2 are independent of dose; AUC rises proportionally with dose. Most drugs behave this way at therapeutic concentrations.

Nonlinear PK — saturable metabolism follows Michaelis-Menten kinetics: v = (Vmax · C) / (Km + C). When C approaches or exceeds Km, clearance falls and small dose increases produce disproportionate concentration rises. Phenytoin (Km ≈ 4 mg/L, Vmax ≈ 7 mg/kg/day) is the classic example: a 100 mg/day increment can carry a patient from subtherapeutic to toxic. Other examples: ethanol (zero-order at social doses), high-dose aspirin, theophylline at high doses.

Loading Dose, Maintenance Dose, and TDM

Maintenance dose rate = Css,target · CL (for IV infusion) or Css,avg · CL / F (oral).

Loading dose = Css,target · Vd / F; rapidly achieves therapeutic levels for drugs with long half-lives (amiodarone, digoxin, phenytoin, vancomycin).

Peak (Cmax) and trough (Cmin) samples bracket the dosing interval; for aminoglycosides, peaks assess efficacy and troughs avoid nephrotoxicity. Vancomycin troughs (10-20 mg/L) target nephrotoxicity avoidance; newer Bayesian dosing uses AUC/MIC ratios.

Therapeutic drug monitoring (TDM) is essential for narrow-therapeutic-index drugs: aminoglycosides, vancomycin, digoxin, phenytoin, lithium, warfarin (INR), cyclosporine, tacrolimus, and anti-epileptics. Sampling at trough (just before next dose) is the standard for steady-state assessment.

Loading diagram... Two-Compartment Pharmacokinetic Model with IV Bolus Concentration-Time Profile

Plasma Concentration vs Time — One-Compartment IV Bolus with Repeated Oral Dosing Reaching Steady State